Published by Peptide Protocols · Reviewed September 2026 · How we make these pages · Educational & research purposes only — not medical advice.
2026 has been the most eventful year for peptide regulation in a long time — and the headlines have been confusing. Here's the plain-English version of the two changes that actually matter, with links to the primary sources so you can read them yourself.
On April 30, 2026, the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the "503B bulks list" — the list that lets large outsourcing facilities compound a drug from bulk raw material. The agency's position: with the branded products no longer in shortage, there's no clinical need for industrial-scale compounding of these three.
Importantly, patient-specific 503A compounding — where a licensed pharmacy makes a preparation for one named patient with a documented medical need — was not the target of this action and remains lawful. This is the difference between "a factory making thousands of vials" and "your pharmacist filling one prescription."
Separately, on the research-peptide side, HHS Secretary Robert F. Kennedy Jr. announced on February 27, 2026 a review of 14 previously restricted peptides, and by April 15, 2026, 12 were removed from the FDA's Category 2 list (the "may present significant safety risks" bucket that blocks compounding) — including BPC-157, largely because the nominations behind those restrictions were withdrawn.
It means exactly what it says: the product is labeled and sold for laboratory and research purposes, not for human use or treatment. That labeling is the responsible standard in this space, and a supplier who understands the regulatory line will use it. Nothing on this site is a recommendation for personal use.
Vial mg + bacteriostatic water mL + your target mcg → mL and U-100 syringe units, instantly. Free, no sign-up, 60+ research peptides preset — plus dedicated calculators and BAC-water charts for BPC-157, retatrutide, tirzepatide, semaglutide, tesamorelin and CJC-1295/ipamorelin.
Open the free peptide calculator →Research & educational use only — never medical advice.
We do not recommend or partner with any peptide supplier. Use the checklist instead: third-party COAs that match your batch and lot, stated purity, clear research-use labeling, real support and proper cold-chain shipping.
The supplier checklist →Educational content only. Confirm the legal status where you live before ordering anything.
Not automatically — the April 30, 2026 FDA action proposes to end large-scale 503B compounding of semaglutide, tirzepatide, and liraglutide, but patient-specific 503A compounding with documented medical need remains lawful. Read the FDA's own notice for the specifics.
It was removed from the FDA's Category 2 list in April 2026, but it was not moved to the permitted (Category 1) list and is not an FDA-approved drug. It remains in a regulatory gray zone; confirm your local rules.
The FDA's press announcement on the 503B bulks list and independent regulatory summaries are linked throughout this article. Always prefer the primary FDA source over secondhand headlines.
Our plain-English guides and the Universal Logbook help you track what you're researching, accurately — whatever the regulatory weather.
Browse the shop on Etsy →The one formula, a BAC-water chart, and the 10 most-researched beginner peptides — the math done for you. Print it for the fridge.
🎁 Send me the free cheat sheet →